Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

2 Pages (Click to Jump) V   1 2 >   
 
  
Reply to this topic

4DX, 4DMedical Ltd
nipper
post Posted: Apr 8 2021, 10:09 AM
  Quote Post


Posts: 8,696
Thanks: 2713


In Reply To: nipper's post @ Mar 31 2021, 04:14 PM

massive scaleback .... put in for $12,500 and got $2,250 in the SPP.



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Mar 31 2021, 04:14 PM
  Quote Post


Posts: 8,696
Thanks: 2713


In Reply To: nipper's post @ Mar 26 2021, 10:29 AM

The SPP was strongly supported by existing eligible shareholders and was substantially oversubscribed. The Company received 1,873 applications totalling approximately $32 million at the issue price of $1.55, the same issue price as the successful $40 million institutional placement completed on 4 March 2021.

Given the response to the SPP and to accommodate the outstanding support of existing shareholders, 4DMedical's Board of Directors has exercised its discretion to increase the SPP offer to $6 million from the original $3 million targeted.

..x..x..x..x..x..x.x.x.x.x.x

And came across this in an announcement by Predictive Analytics and Artificial Intelligence company Houston We Have (ASX:HWH) , acquiring ECHO IQ, another specialist artificial intelligence company focused on using powerful diagnostic triage technology.
QUOTE
Leading imaging businesses such as GE have already signaled the importance of AI with the development of Edison which is designed to help health providers take advantage of data in new and significant ways. Their new AI powered XRay device is reducing the time needed to detect critical lung issues.

I never thought 4DX had a stranglehold, even with their patents and early start. Let's hope for rapid and positive results, now it has a Strong balance sheet position with cash balance exceeding $80 million.



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Mar 26 2021, 10:29 AM
  Quote Post


Posts: 8,696
Thanks: 2713


In Reply To: nipper's post @ Mar 11 2021, 01:49 PM

Am looking to put some into the SPP

But, after it closed an oversubscribed $40 million placement to institutional investors, priced at $1.55 per share and it had also been awarded a $28.9 million from the government's Medical Research Future Fund, they are only wanting to take in $1M from shareholders.

I feel a scaleback coming on; especially as the last few days, trading has lifted from low $1.50's to above $1.80



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Mar 11 2021, 01:49 PM
  Quote Post


Posts: 8,696
Thanks: 2713


In Reply To: nipper's post @ Mar 6 2021, 12:17 PM

SPP also at $1.55 to be offered, open for the last 2 weeks of March...... pity the share price of 4DX is now under that; as low as $1.51 today



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Mar 6 2021, 12:17 PM
  Quote Post


Posts: 8,696
Thanks: 2713


In Reply To: nipper's post @ Mar 2 2021, 08:16 PM

Lung imaging software company 4DMedical has secured almost $70 million in funding from a mix of government and institutional investors to develop a lung scanner that emits a fraction of the radiation of a CT machine.

On Thursday the company said it had closed an oversubscribed $40 million placement to institutional investors, priced at $1.55 per share and it had also been awarded a $28.9 million from the government’s Medical Research Future Fund, via its Australian Lung Health Initiative consortium.

The announcement is the beginning of a long-held goal for 4DMedical chief executive Andreas Fouras, who envisaged creating such a device when he founded the company in 2012.
QUOTE
Our current XV technology is the only product that connects to existing equipment all around the world and offers the very best scan possible today. The XVD product is an offering that will sit side by side with the existing hospital equipment out there, Dr Fouras said.

We have a clear timeline, we've done our homework. We expect to have a system in an Australian hospital early next year, then we expect to be in front of the regulator later on in that year and then the year after (2023) we'll have product in the market.
We already have some customers saying they want this product. The level of interest is very solid, it is international and it's even from folks that aren't exposed to the XV technology currently.


Today, lung imaging is traditionally done on a CT scan machine, which allows radiologists to look at different levels, or slices, of the lungs using a rotating X-ray beam. While that gives an overall picture of how much air the lungs take in, with 4DMedical's software in the market today, analysts can determine if there are parts of the lungs getting less air.

The downside of these scans, however, is the high amount of radiation they involve, in comparison with an X-ray.

The first iteration of 4DMedical's XVD Scanner, Dr Fouras says, will have a similar level of radiation to an X-ray (about 1 per cent of the amount of a CT scan), while the second generation of the product they intend to have 10 times less the radiation of a traditional X-ray, or 1000 times less than a CT.

The scans will also be faster, taking just 10 seconds versus six minutes in a CT....
https://www.afr.com/technology/4dmedical-ba...20210304-p577qm



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Mar 2 2021, 08:16 PM
  Quote Post


Posts: 8,696
Thanks: 2713


got to $1.70 ... I wonder if this will help things
QUOTE
4DMEDICAL LED CONSORTIUM AWARDED $28.9M MRFF GRANT TO DELIVER THE WORLD’S FIRST DEDICATED LUNG FUNCTION SCANNER


• Australian Lung Health Initiative Pty Ltd (ALHI), a consortium incorporated and led by 4DMedical, has been awarded $28.9 million in funding over the next five years as part of the Federal Government's Medical Research Future Fund (MRFF) Frontier Health and Medical Research initiative (Stage Two)
• The funding will be used by ALHI to develop two generations of dedicated, low dose lung function scanners (XVD Scanners™) that provide safe, easy and rapid lung analysis of adults and children
• 4DMedical has been granted the exclusive right to commercialise XVD Scanners and will be responsible for the global sale and marketing of XVD Scanners in the field of lung health
• XVD Scanners will be integrated with 4DMedical’s proprietary XV Technology™, significantly increasing the addressable revenue opportunity and driving the adoption of the Company’s Softwareas-a-Service (SaaS) offering at medical institutions
• ALHI was previously awarded $1.1 million in Stage One funding that was used to successfully develop and deliver a Generation One XVD Scanner concept
• Stage Two of the project aims to bring Generation One and Generation Two scanners to commercialisation, with first units expected to be deployed in Australian hospitals for clinical trials within the next 12 months





--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 


nipper
post Posted: Feb 25 2021, 11:09 AM
  Quote Post


Posts: 8,696
Thanks: 2713


In Reply To: nipper's post @ Feb 10 2021, 08:14 PM

and kept going, another 40+c lower. Early optimism tempered by (belated?) later realism?
QUOTE
As 4DMedical commences its commercialisation phase, the Company's strategy remains focused on securing clinical pilots and completing clinical trials with leading hospitals and healthcare institutions.

Clinical trials are independent research studies that validate the accuracy of 4DMedical's XV LVAS on patients with specific indications and respiratory diseases. The results of clinical trials are published in medical journals and can assist in driving the adoption of XV LVAS for specific use cases. The Company currently has a strong pipeline of clinical trials at various stages of development and focused on addressing some of the most complex, prevalent, and costly lung conditions.

Clinical pilots allow hospitals and medical institutions to implement and review XV LVAS in standard clinical practice ahead of potential commercial integration. 4DMedical is in discussion with several potential clinical pilot partners which it will aim to convert into customers and/or reference sites.
The combination of clinical pilots and clinical trials will form the foundation to securing scale and, importantly, assist the Company to capture a significant portion of the US$31 billion global respiratory diagnostics market.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Feb 10 2021, 08:14 PM
  Quote Post


Posts: 8,696
Thanks: 2713


Sold half my 4DX yesterday for a few cents down. I may have entered too late; the selling keeps coming.

Will watch and wait. Comfortable with company as a concept, but will it win the West?



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 27 2021, 08:30 AM
  Quote Post


Posts: 8,696
Thanks: 2713


and another step in the right direction
QUOTE
• 4DMedical to commence the first U.S. clinical pilot of its XV Lung Ventilation Analysis Software offering at St. Joseph Hospital located in Orange County, California
• XV LVAS will be used to assist in screening for a variety of lung conditions, including COVID-19
• The clinical pilot follows on from XV LVAS receiving FDA 510(k) clearance in May 2020 and Class 1 approval from the Australian Therapeutic Goods Administration in September 2020




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 4 2021, 05:51 PM
  Quote Post


Posts: 8,696
Thanks: 2713


.....
QUOTE
....In order for the company to succeed, they will need to build up more and more evidence to prove that their innovation is sufficiently better than the alternatives that hospitals (and therefore patients) should pay to use it.

The process of convincing the medical establishment to use new technology is not easy, because clinicians typically want to be sure, and need to be convinced that the new technology brings real benefits. This process usually takes longer than impatient investors are willing to wait, and ultimately relies on convincing diverse parties that this technology can improve outcomes and reduce the cost of total care......

...
QUOTE
... [CEO Andreas] Fouras can explain why his technology is better in a single sentence. He says: By imaging the breathing lungs, it is possible to see what is really important, which is how they work, not what they look like. This is important, because they are not just trying to replicate human diagnostic abilities with machines (which is a typical faux "innovation" that rarely succeeds) but actually to improve diagnostic ability. And I think that is what this company is trying to do. Only if you give better results to patients and payers alike will you stand a chance of changing behaviour quickly. 4DX seems to understand this, and argues that they can offer competitive pricing below incumbent technologies....


https://arichlife.com.au/why-i-bought-some-...ve-stock-i-own/



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
 


2 Pages (Click to Jump) V   1 2 >

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING